What Анвифен Treats: Main Uses and Benefits

Aminophenylbutyric Acid (Анвифен) is commonly used across domains where additional symptomatic support is needed, applied in clinical settings marked by temporary physiological imbalance. It is utilized to help with symptoms related to anxiety and tension, and is considered relevant for managing indications such as post-traumatic stress and vestibular disorders.

Therapeutic Support Domains

The medicine is used for managing conditions characterized by periods of heightened symptoms, including chronic anxiety, tension, asthenia (mental exhaustion), and specific sleep disturbances related to psychological distress. It is also applied in neuro-sensory contexts to address dizziness and vertigo associated with vestibular issues, and as prophylaxis for motion sickness. The support provided may help ease the overall symptom burden, which supports patients during episodes of heightened discomfort.

“The support provided assists with maintaining functional stability.”

---

Quick Fact: Relief for Tension and Asthenia

This medicine is applicable within therapeutic areas involving heightened responses and is commonly used to help with symptoms that interfere with daily functioning, providing support during difficult episodes.

The eligibility profile for Анвифен (Aminophenylbutyric Acid/Phenibut) is determined by the official prescribing information, establishing absolute prohibitions and conditional restrictions based on population group and comorbidity.

Eligibility Scope

Populations for whom use is contraindicated: Use is formally prohibited for pregnant individuals and breastfeeding mothers. It is also contraindicated for all children under 3 years of age, patients with known hypersensitivity to the components, and individuals with severe liver insufficiency or severe ulcerative lesions of the gastrointestinal tract (GIT).

Age and Comorbidity Rules: The medicine is approved for adults and the pediatric population aged 3 years and older. However, eligibility is restricted for certain groups. Conditional use is required with caution for patients with existing hepatic insufficiency or erosive/ulcerative lesions of the GIT. The regulatory profile includes specific, reduced maximum single dose limitations for the geriatric population (patients over 60 years).

Eligibility Classifications

Eligibility severity classification (as defined in official documents): The official label defines eligibility using Contraindication (absolute prohibition) and Use with Caution (conditional restriction). The regulatory basis for these limitations is primarily dependent on age, physiological state, and organ function.

Interactions with other medicines and products

The interaction profile for Анвифен (Aminophenylbutyric Acid) is defined by its effect on the central nervous system (CNS), resulting in a documented pharmacodynamic reinforcement with other substances.

Interaction Scope	Official Regulatory Information
Medicinal Product Categories	CNS Depressants, including Anxiolytics, Antipsychotics (Neuroleptics), Opioid Analgesics, Sedatives, and Anticonvulsants.
Specific Interacting Substances	Alcohol (Ethanol) is explicitly noted as an interacting substance.
Mechanistic Basis	Pharmacodynamic Reinforcement: Documented as mutual potentiation of central depressant effects. Pharmacokinetic: No specific enzyme (CYP) or transporter-mediated interactions are documented, as the drug is largely excreted unchanged.

Interaction Classification	Official Regulatory Information
Severity Classification	Classified as a Clinically Significant Interaction due to the risk of reinforcement; None are formally classified as Contraindicated (prohibited).
Timing/Population Rules	None documented. Official labeling does not mandate hour-based separation of doses or note population-specific interaction cautions.

Official Interaction Statements:

• Co-administration with other CNS depressants results in the mutual potentiation of the central depressant action.
• The interaction is noted to prolong the action of co-administered hypnotics and neuroleptics.
• The effects of Alcohol (Ethanol) are explicitly potentiated by this medicine.

The overall interaction structure is centered on the officially documented risk of pharmacodynamic reinforcement across various categories of CNS depressants. This profile is not governed by pharmacokinetic inhibition or induction concerns, as regulatory data confirms the active ingredient is primarily eliminated in its original form. This defines the constraint framework for co-administration.

Enhancement of Central Inhibitory Control

This mechanism involves the drug acting as an agonist at central GABA B receptors, which mediate a significant portion of neural inhibition in the brain. The resulting enhancement of the GABAergic system decreases overall neural discharge frequency, influencing the equilibrium of electrochemical activity within the central nervous system.

---

Modulation of Neurotransmitter Release

The drug modulates the activity of the alpha-2-delta (,alpha2delta) subunit of voltage-dependent calcium channels (VDCCs) on presynaptic nerve endings. This molecular interaction limits calcium influx, thereby decreasing the efficiency of sequential synaptic activation by reducing the presynaptic release of excitatory neurotransmitters.

---

Influence on Trace Amine Signaling

This action is distinct, involving the drug's role in the trace amine system through antagonism of the effects of beta-phenethylamine (PEA). This antagonism influences the effects of PEA on neural excitability, which affects signal transduction dynamics across multiple pathways in the central nervous system.

How to Use Анвифен

This section describes the administration guidelines for Анвифен (Aminophenylbutyric Acid), outlining the protocols associated with the use of this medication.

The medicine is supplied as oral Capsules or Tablets in strengths of 250 mg and 500 mg, or as a Solution for Infusion. The primary route is Oral administration, while the solution form is designated for Intravenous (IV) Infusion.

Dosing and Administration Protocol

The standard adult dosing schedule involves a daily total intake that typically ranges between 250 mg and 2000 mg (2 g). This total daily dose is administered in divided doses, generally scheduled up to three times daily. The oral form is intended to be swallowed with water.

Treatment is typically structured into defined, time-bound courses or cycles. The medicine is not typically used for indefinite continuous periods. Discontinuation after a prolonged course requires a procedural step: the dose must be tapered gradually rather than stopped abruptly. Administration guidelines also establish a usage boundary in children, as the medicine is generally not used in children younger than two years of age.

Анвифен (Anvifen): Recent Clinical Evidence

Clinical research on the compound in Анвифен (Phenibut) is primarily focused on its use for anxiety disorders and sleep disturbances (insomnia), drawing largely from studies conducted in Eastern European countries where the drug is registered and prescribed. Evidence aims to understand the substance's activity as a GABA-mimetic, primarily targeting the GABA B receptor.

---

Trial Outcomes for Anxiety and Sleep

Studies have assessed the outcomes of the drug in adults experiencing symptoms of anxiety or insomnia.

• Anxiety: Trials have explored the effect on generalized anxiety symptoms using standardized rating scales, such as the Hospital Anxiety and Depression Scale (HADS). Some research comparing short-term (e.g., 21 days) versus prolonged (e.g., 60 days) treatment courses observed that longer duration of use was associated with more sustained outcomes following the completion of the study period.
• Sleep: Research has examined the use of the compound in conditions characterized by comorbid insomnia, including in older adults, to assess changes in sleep quality. The compound has also been studied in relation to symptoms such as dizziness and post-COVID fatigue/brain fog syndrome, exploring its effect on associated anxiety and asthenia.

---

Safety and Tolerability Observations

Systematic reviews analyzing the safety data from multiple clinical trials (involving hundreds of participants) have reported on the incidence of adverse events associated with therapeutic doses.

Observation Category	Summary of Study Findings
Adverse Events	The overall reported incidence of adverse events in clinical trials was low.
Most Common Events	The event most frequently reported in the trials was somnolence (drowsiness).
High Dose Effects	Research indicates that the use of high doses (over 2 g per day) may be associated with a higher incidence of adverse events, including cardiovascular symptoms and hallucinations.

Common questions about Анвифен (FAQ)

Q: What should I do if I forget to take my dose of Анвифен?

A: Official regulatory documents indicate that the usual approach is to continue taking the next scheduled dose as planned. The official documentation does not include instructions to double the next dose or otherwise compensate for a missed dose.

Q: Is Анвифен safe to use if I have a history of liver issues?

A: Official safety information lists liver insufficiency or failure as a formal contraindication, meaning the medicine is formally prohibited in this condition. Conditional use is required with caution for patients with pre-existing hepatic insufficiency (impaired liver function that is not total failure), and monitoring of liver function is typically recommended.

Q: What is the recommended maximum duration of use for Анвифен?

A: Official product information describes a standard treatment course ranging between 2 to 3 weeks. This duration may be extended up to 4 to 6 weeks if, based on a healthcare provider's assessment, the clinical need requires it.

Q: Is it safe to stop taking Анвифен suddenly?

A: Official information explicitly advises against stopping the medicine abruptly. The dose needs to be tapered gradually over time to prevent the occurrence of severe withdrawal symptoms.

Q: What are the less common, but serious, side effects of Анвифен?

A: Official sources document that the overall incidence of adverse events at standard therapeutic doses is low. However, higher intake (over 2 grams per day) may be associated with increased reporting of serious adverse events, such as cardiovascular symptoms and visual or auditory hallucinations.

Q: Can I take Анвифен if I have a kidney condition?

A: Regulatory warnings note that while pre-existing kidney conditions are not listed as a general contraindication, renal impairment is documented as a risk in cases of overdose or excessive intake. Kidney function is not generally cited as a restriction for typical, authorized use.

Q: Is it better to take Анвифен with or without food?

A: The official method of administration is described as taking the drug orally before meals, providing guidance on the timing relative to food intake. This is intended to follow the protocols outlined in the regulatory label.

Q: Is it possible to take too much Анвифен?

A: Yes. Official warnings address the risk of Overdose and Toxicity, which can lead to severe Central Nervous System (CNS) depression, loss of consciousness, motor incoordination, and potential damage to the liver and kidneys.

Q: What is the half-life of Анвифен?

A: Based on studies in healthy volunteers, the elimination half-life (t1/2) of the active ingredient is approximately 5.3 hours. The half-life is a measure of the time required for the amount of the drug in the body to be reduced by half.

Q: Does Анвифен need to be taken at a specific time of day?

A: The medicine is generally prescribed in divided doses throughout the day. While no specific time is globally mandated, administration guidelines sometimes structure the dosing, for example, involving doses during the day and a larger dose at night to manage associated sleep issues.

Q: Does Анвифен help with concentration or focus?

A: The drug is formally classified by health authorities as a Nootropic, in addition to being an anxiolytic. In its medical context, the term nootropic refers to a substance that may influence or support cognitive functions, which can include aspects like concentration and focus.

How to Store and Dispose of Анвифен?

The official regulatory instructions for storing and disposing of this medicine (Phenibut) are designed to maintain product quality and ensure safety, based strictly on government-issued labeling.

Official Storage Requirements

Storage Component	Requirement
Temperature	Store at a temperature not exceeding 25^circC (or 30^circC, depending on region).
Protection	Keep in the original package and in a dry place to protect the product from light and moisture.
Accessibility	Keep out of the sight and reach of children.
Stability	Do not use the medicine after the expiry date printed on the carton and blister pack.

Official Disposal Rules

Unused or expired product must be managed safely to prevent environmental contamination. Regulatory guidelines strictly advise against disposing of this medicine via household waste or wastewater (e.g., flushing down the toilet). Instead, return any unused medicine to a pharmacist or local waste disposal service for safe and proper destruction.